FDA approves first treatment for skin conditions that cause persistent sores, redosable gene therapy – STAT

FDA approves first treatment for skin conditions that cause persistent sores, redosable gene therapySTAT
Krystal’s Vyjuvek becomes first FDA-approved topical gene therapy to treat rare skin diseaseFiercePharma
Rare skin blistering condition gets first drug approvedMedpage today
In a historic victory for people living with DEB and their families, the FDA announced its approval of Krystal Biotech’s VYJUVEK™ for the treatment of dystrophic epidermolysis bullosa (DEB).business thread
FDA approves first-ever topical gene therapymedical landscape